(VIANEWS) – LGI Homes (LGIH), First Bank (FRBA), Boston Scientific (BSX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. LGI Homes (LGIH)
40.2% sales growth and 12.61% return on equity
LGI Homes, Inc. designs, constructs, and sells homes in the United States. It offers entry-level homes, such as detached and attached homes, and move-up homes under the LGI Homes brand name; and luxury series homes under the Terrata Homes brand name. As of December 31, 2020, it owned 113 communities. The company serves in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia, and Pennsylvania. LGI Homes, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, LGI Homes has a trailing twelve months EPS of $8.35.
PE Ratio
LGI Homes has a trailing twelve months price to earnings ratio of 11.21. Meaning, the purchaser of the share is investing $11.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.61%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 43.4% and positive 74.5% for the next.
Volume
Today’s last reported volume for LGI Homes is 117872 which is 37.54% below its average volume of 188745.
Moving Average
LGI Homes’s worth is way under its 50-day moving average of $113.20 and way below its 200-day moving average of $116.13.
2. First Bank (FRBA)
20.7% sales growth and 11.64% return on equity
First Bank provides various banking products and services to individuals, businesses, and governmental entities. The company accepts various deposits, including non-interest bearing demand deposits, interest bearing demand accounts, money market accounts, savings accounts, and certificates of deposit, as well as commercial checking accounts. Its loan products include commercial and industrial loans; commercial real estate loans, such as owner-occupied, investor, construction and development, and multi-family loans; residential real estate loans comprising residential mortgages, first and second lien home equity loans, and revolving lines of credit; and consumer and other loans that include auto, personal, and traditional installment loans. The company also provides electronic banking services, including Internet and mobile banking, electronic bill payment, and banking by phone, as well as ATM and debit cards, and wire and ACH transfer services; remote deposit capture; and cash management services. As of December 31, 2021, it operated 18 full-service branches in Cinnaminson, Cranbury, Delanco, Denville, Ewing, Flemington, Hamilton, Hamilton, Lawrence, Mercerville, Pennington, Randolph, Somerset, and Williamstown counties in New Jersey, as well as Doylestown, Trevose, Warminster, and West Chester counties in Pennsylvania. First Bank was incorporated in 2007 and is headquartered in Hamilton, New Jersey.
Earnings Per Share
As for profitability, First Bank has a trailing twelve months EPS of $1.69.
PE Ratio
First Bank has a trailing twelve months price to earnings ratio of 6.66. Meaning, the purchaser of the share is investing $6.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.64%.
Sales Growth
First Bank’s sales growth is 15.2% for the current quarter and 20.7% for the next.
Previous days news about First Bank(FRBA)
- According to Zacks on Thursday, 19 October, "A quarter ago, it was expected that this holding company for Southern First Bank would post earnings of $0.32 per share when it actually produced earnings of $0.31, delivering a surprise of -3.13%."
3. Boston Scientific (BSX)
12% sales growth and 5.1% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.6.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 84.18. Meaning, the purchaser of the share is investing $84.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Sales Growth
Boston Scientific’s sales growth is 9.6% for the current quarter and 12% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 13.4B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Boston Scientific’s EBITDA is 124.52.
Previous days news about Boston Scientific(BSX)
- The zacks analyst blog highlights Visa, AbbVie, BHP group, caterpillar and Boston Scientific. According to Zacks on Friday, 20 October, "(BHP Quick QuoteBHP – Free Report) , Caterpillar Inc. (CAT Quick QuoteCAT – Free Report) and Boston Scientific Corp. (BSX Quick QuoteBSX – Free Report) .", "Efforts to make operations more efficient through technology will drive earnings.(You can read the full research report on BHP here >>>)Other noteworthy reports we are featuring today include Caterpillar Inc. and Boston Scientific Corp."
4. Terreno Realty Corporation (TRNO)
9% sales growth and 6.07% return on equity
Terreno Realty Corporation and together with its subsidiaries, the “Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these condensed notes to the consolidated financial statements are unaudited. As of September 30, 2020, the Company owned 219 buildings aggregating approximately 13.1 million square feet, 22 improved land parcels consisting of approximately 85.0 acres and one property under redevelopment expected to contain approximately 0.2 million square feet upon completion. The Company is an internally managed Maryland corporation and elected to be taxed as a real estate investment trust (“REIT”) under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with its taxable year ended December 31, 2010.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $1.84.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 30.2. Meaning, the purchaser of the share is investing $30.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.07%.
5. Globus Medical (GMED)
5.8% sales growth and 11.09% return on equity
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Earnings Per Share
As for profitability, Globus Medical has a trailing twelve months EPS of $2.05.
PE Ratio
Globus Medical has a trailing twelve months price to earnings ratio of 26.02. Meaning, the purchaser of the share is investing $26.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.09%.
6. Washington Federal (WAFD)
5.7% sales growth and 10.95% return on equity
Washington Federal, Inc. operates as the bank holding company for Washington Federal Bank, National Association that provides lending, depository, insurance, and other banking services in the United States. The company accepts deposit products, including business and personal checking accounts, and term certificates of deposit, as well as money market accounts and passbook savings accounts. It also provides single-family residential, construction, land acquisition and development, consumer lot, multi-family residential, commercial and industrial, commercial real estate, home equity, and consumer loans. In addition, the company offers insurance brokerage services, such as individual and business insurance policies to customers and general public; holds and markets real estate properties; mobile and internet banking services; debit and credit cards; and acts as trustee. It serves consumers, mid-sized and large businesses, and owners and developers of commercial real estate. As of September 30, 2020, the company had 234 branches located in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, and Texas. Washington Federal, Inc. was founded in 1917 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Washington Federal has a trailing twelve months EPS of $4.07.
PE Ratio
Washington Federal has a trailing twelve months price to earnings ratio of 6.15. Meaning, the purchaser of the share is investing $6.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.95%.
Sales Growth
Washington Federal’s sales growth is 0.9% for the current quarter and 5.7% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 26.7% and a negative 9.5%, respectively.
Moving Average
Washington Federal’s worth is under its 50-day moving average of $26.75 and way under its 200-day moving average of $29.55.
